Literature DB >> 6993420

Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine.

P Stensrud, O Sjaastad.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6993420     DOI: 10.1111/j.1526-4610.1980.h2004006.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


× No keyword cloud information.
  15 in total

Review 1.  Pharmacology of antimigraine drugs.

Authors:  P R Saxena; M O Den Boer
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 2.  [Alternatives to beta blockers in preventive migraine treatment].

Authors:  S Evers
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

3.  A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.

Authors:  Elham Bidabadi; Mehryar Mashouf
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

4.  Migraine Prophylaxis: A pharmacologic approach.

Authors:  I Danys
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 5.  The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.

Authors:  V Limmroth; M C Michel
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 6.  The clinician's approach to the management of headache.

Authors:  M Maizels
Journal:  West J Med       Date:  1998-03

Review 7.  Strategies for diagnosing and managing medication-induced headache.

Authors:  J G Edmeads; M J Gawel; J Vickers
Journal:  Can Fam Physician       Date:  1997-07       Impact factor: 3.275

Review 8.  A practical guide to the management and prevention of migraine.

Authors:  H C Diener; H Kaube; V Limmroth
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

9.  [Drug treatment as migraine prophylaxis.].

Authors:  H C Diener; A Ziegler
Journal:  Schmerz       Date:  1989-12       Impact factor: 1.107

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.